CLDX
Celldex Therapeutics Inc.

9,723
Mkt Cap
$1.97B
Volume
733,694.00
52W High
$31.99
52W Low
$14.40
PE Ratio
-7.61
CLDX Fundamentals
Price
$28.54
Prev Close
$29.64
Open
$29.38
50D MA
$26.57
Beta
1.14
Avg. Volume
956,330.66
EPS (Annual)
-$3.90
P/B
3.74
Rev/Employee
$7,803.03
$1,292.18
Loading...
Loading...
News
all
press releases
Eventide Asset Management LLC Has $48.10 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX
Eventide Asset Management LLC raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 37.1% in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP
Commodore Capital LP trimmed its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 12.2% during the 3rd quarter, according to the company in its most recent Form 13F filing...
MarketBeat·3d ago
News Placeholder
Braidwell LP Makes New Investment in Celldex Therapeutics, Inc. $CLDX
Braidwell LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange...
MarketBeat·4d ago
News Placeholder
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts
Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion at the Leerink Partners Global Healthcare Conference, with a major focus...
MarketBeat·4d ago
News Placeholder
Celldex Therapeutics, Inc. $CLDX Shares Purchased by American Century Companies Inc.
American Century Companies Inc. lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 4.6% in the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·9d ago
News Placeholder
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Still a Buy?
Celldex Therapeutics (NASDAQ:CLDX) Hits New 52-Week High - Time to Buy...
MarketBeat·9d ago
News Placeholder
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference
Executives from Celldex Therapeutics (NASDAQ:CLDX) outlined a busy year of clinical and development milestones at the TD Cowen Healthcare Conference, highlighting completed enrollments in two Phase 3...
MarketBeat·10d ago
News Placeholder
TD Asset Management Inc Decreases Stake in Celldex Therapeutics, Inc. $CLDX
TD Asset Management Inc cut its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 27.7% during the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·13d ago
News Placeholder
Propel Bio Management LLC Makes New $4.01 Million Investment in Celldex Therapeutics, Inc. $CLDX
Propel Bio Management LLC bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·13d ago
News Placeholder
Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX
Segall Bryant & Hamill LLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 36.3% during the 3rd quarter, according to the company in its most recent Form 13F filing...
MarketBeat·14d ago
<
1
2
...
>

Latest CLDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.